Print

JPT Peptide Technologies GmbH and The Institute for Medical Immunology at the Charité in Berlin Announce Collaboration on Chronic Fatigue Syndrome  
1/30/2013 9:43:40 AM

BERLIN--(BUSINESS WIRE)--JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of BioNTech AG (Mainz, Germany), and The Institute for Medical Immunology at the Charité in Berlin today announced a collaborative agreement on the development of serological peptide markers for the differential diagnosis of chronic fatigue syndrome (CFS).
//-->